Quality of life and health status with zoledronic acid and generic alendronate--a secondary analysis of the Rapid Onset and Sustained Efficacy (ROSE) study in postmenopausal women with low bone mass
| Autor: | K. Articus, P. Hadji, R. Moericke, D. Gamerdinger, Monika Baier, Volker Ziller, Peter H. Kann, W. Spieler |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
medicine.medical_specialty
Psychometrics Endocrinology Diabetes and Metabolism Low bone mass Health Status Osteoporosis Administration Oral Zoledronic Acid Drug Administration Schedule law.invention Medication Adherence Quality of life Randomized controlled trial law Secondary analysis Internal medicine Activities of Daily Living medicine Drugs Generic Humans Infusions Intravenous Osteoporosis Postmenopausal Aged Aged 80 and over Alendronate Bone Density Conservation Agents Diphosphonates business.industry Imidazoles Patient Preference Middle Aged medicine.disease Rheumatology Zoledronic acid Rapid onset Physical therapy Quality of Life Female business medicine.drug |
| Zdroj: | Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 23(7) |
| ISSN: | 1433-2965 |
| Popis: | The ROSE study compared annual infusion with zoledronic acid and weekly generic alendronate. No significant differences in quality of life or health status between treatment groups were observed. Adherence to alendronate during the study was high, with 80.9% of patients achieving adequate adherence.A secondary analysis to evaluate quality of life, health status, adherence to alendronate and therapy preference in postmenopausal women with low bone mass who received treatment with zoledronic acid or alendronate was conducted.Postmenopausal women with low bone mass were randomised 2:1 to receive an annual infusion of zoledronic acid or weekly oral generic alendronate in this open-label, multicentre study. Changes in quality of life and health status were assessed using questionnaires at baseline and month 12. Adherence to alendronate was assessed by the investigator and/or study personnel, and subjective therapy preference was assessed using a questionnaire at month 12.Patients were randomised to zoledronic acid (n = 408) and alendronate (n = 191). Overall, there were no significant differences in quality of life between zoledronic acid and alendronate. However, improvements in quality of life with zoledronic acid versus alendronate could be detected by posthoc analysis in patients with previous fractures. There were no significant differences in health status between patients receiving zoledronic acid or alendronate. Adherence to alendronate during the study was high, with 80.9% of patients achieving adequate adherence. A total of 81% of patients who had received zoledronic acid indicated that they would prefer to continue with that treatment, and 43% of the patients who received oral alendronate would like to switch to zoledronic acid.There were no significant differences in quality of life between patients receiving zoledronic acid or alendronate. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink